---
title: "Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/269107376.md"
description: "Anupam Rama from J.P. Morgan rates Vor Biopharma (VOR) as a Buy due to telitacicept's potential in addressing unmet needs in Myasthenia Gravis and primary Sjögren’s Disease. The drug's valuation disconnect suggests market undervaluation, with a price target of $43 by December 2026. Resolving cash constraints could enhance stock value. Rama's analysis highlights strategic focus and potential blockbuster sales in the U.S. market."
datetime: "2025-12-09T14:25:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269107376.md)
  - [en](https://longbridge.com/en/news/269107376.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269107376.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/269107376.md) | [繁體中文](https://longbridge.com/zh-HK/news/269107376.md)


# Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs

Anupam Rama, an analyst from J.P. Morgan, has initiated a new Buy rating on Vor Biopharma (VOR).

### TipRanks Cyber Monday Sale

-   Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
-   Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Anupam Rama has given his Buy rating due to a combination of factors that highlight the potential of Vor Biopharma’s telitacicept. The drug, a dual APRIL/BAFF inhibitor, is seen as significantly de-risked due to late-stage data from China, where it is already approved or in the regulatory process for Myasthenia Gravis (MG) and primary Sjögren’s Disease (pSD). Vor Biopharma has strategically chosen to focus on global indications that have substantial unmet needs and less competition, which positions telitacicept as a promising candidate for blockbuster sales in the U.S. market.  
Moreover, Rama points out a valuation disconnect in VOR shares, suggesting that the market has not fully appreciated the probability-adjusted value of telitacicept in MG and pSD. As global studies progress and the financing situation improves, there is potential for the stock to increase in value. The analyst also notes that resolving cash constraints could remove a sentiment overhang, allowing the company to focus on the fundamentals of its promising product. The December 2026 price target of $43 reflects these considerations, with additional upside potential as the MG and pSD programs advance.

Rama covers the Healthcare sector, focusing on stocks such as Oric Pharmaceuticals, IDEAYA Biosciences, and Olema Pharmaceuticals. According to TipRanks, Rama has an average return of 17.1% and a 52.02% success rate on recommended stocks.

### 相关股票

- [Vor BioPharma (VOR.US)](https://longbridge.com/zh-CN/quote/VOR.US.md)

## 相关资讯与研究

- [Vor Biopharma Q4 profit tops estimates on warrant fair value gain](https://longbridge.com/zh-CN/news/281017187.md)
- [Vor Bio Unveils $75 Mln Private Placement To Advance Telitacicept; Stock Up](https://longbridge.com/zh-CN/news/280810208.md)
- [What's Behind The Jump In Vor Biopharma Stock?](https://longbridge.com/zh-CN/news/280820249.md)
- [Vor Biopharma to Highlight Telitacicept at JPM Conference](https://longbridge.com/zh-CN/news/272292535.md)
- [BUZZ-Vor Bio climbs after announcing $75 mln private placement](https://longbridge.com/zh-CN/news/280795805.md)